Lupin receives Crisil ESG rating of 69 for FY26, placed in strong category
- Lupin receives a Crisil ESG rating of 69 for FY26
- The firm is placed in the 'Strong' category by the rating agency
- A Core ESG rating of 65 was also assigned
- The assessment was conducted independently by Crisil
- Disclosure made under SEBI Regulation 30 requirements

*this image is generated using AI for illustrative purposes only.
Lupin has been assigned an Environmental, Social and Governance (ESG) rating of Crisil ESG 69 for FY26 by Crisil ESG Ratings & Analytics Ltd. The assessment places the pharmaceutical company in the 'Strong' category.
The rating agency also assigned a Crisil Core ESG 65 score to the Mumbai-based firm. This evaluation reflects the company's performance across environmental, social, and governance parameters as assessed by the external agency.
Independent Assessment
Crisil ESG Ratings prepared the report independently using publicly available information about Lupin. The company did not engage the rating agency for this specific ESG rating exercise.
Regulatory Disclosure
The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amit Kumar Gupta, Company Secretary and Compliance Officer, signed the communication on August 28, 2026.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.24% | -3.06% | -12.66% | -8.67% | +8.55% | 0.0% |
How might Lupin's 'Strong' ESG rating influence its ability to secure green financing or attract international institutional investors in the coming fiscal year?
What specific operational changes or capital expenditures is Lupin likely to prioritize to improve its Crisil Core ESG score from 65 to a higher tier in FY27?
Could this independent ESG assessment trigger a re-evaluation of Lupin's risk profile by global healthcare partners and supply chain stakeholders?


































